博瑞医药: 2025年半年度报告摘要

Core Viewpoint - The report highlights a significant decline in the financial performance of Bright Gene Bio-Medical Technology Co., Ltd. for the first half of 2025, with a notable drop in revenue and net profit compared to the same period last year [1][2]. Financial Performance - Total assets increased to approximately 5.38 billion RMB, reflecting a 4.41% increase from the previous year [1]. - Operating revenue for the first half of 2025 was approximately 537.44 million RMB, representing an 18.28% decrease compared to 657.69 million RMB in the same period last year [1]. - The total profit for the period was a loss of approximately 5.02 million RMB, a stark contrast to a profit of 94.31 million RMB in the previous year, marking a 105.32% decline [1]. - Net profit attributable to shareholders was approximately 14.37 million RMB, down 86.35% from 105.24 million RMB in the previous year [1]. Shareholder Information - The total number of shareholders as of the report date was 9,568 [2]. - Major shareholders include Yuan Jiandong, holding 26.86% of shares, and Zhong Weifang, holding 5.33% of shares, with a familial relationship indicating they are the actual controllers of the company [4].